Literature DB >> 22120758

Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes.

Dongmei Lai1, Fangyuan Wang, Yifei Chen, Chunhui Wang, Sha Liu, Bufeng Lu, Xirui Ge, Lihe Guo.   

Abstract

Ovarian cancer comprises a small population of cancer stem cells (CSCs) that are responsible for tumor maintenance and resistant to cancer therapies, it would be desirable to develop a therapy that could selectively target ovarian CSCs. Recently, cellular immune-based therapies have improved the prognosis of cancer patients clinically. In this study, we isolated a subset of ovarian cancer sphere cells that possess CSC properties and explored the cell cytotoxicity of γδ T cells to ovarian cancer sphere cells using a transwell cocultured cell system. The proliferation rate of the cancer sphere cells decreased to 40% after cocultured with γδ T cells. The γδ T cells increased the sensitivity of SK-OV-3 sphere cells to chemotherapeutic drugs. After the treatment of γδ T cells, the expression of stem cell marker genes decreased in sphere cells, while the expression of HLA-DR antigen on tumor cells was increased in a time-dependent manner. Further, γδ T cells induced G2/M phase cell cycle arrest and subsequent apoptosis in SK-OV-3 sphere cells. Xenograft mouse models demonstrated that γδ T cells dramatically reduced the tumor burden. Notably, the level of IL-17 production significantly increased after cocultured with γδ T cells. We conclude that γδ T cells may efficiently kill ovarian CSCs through IL-17 production and represent a promising immunotherapy for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22120758     DOI: 10.1007/s00262-011-1166-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

1.  Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.

Authors:  Drew C Deniger; Kirsten Switzer; Tiejuan Mi; Sourindra Maiti; Lenka Hurton; Harjeet Singh; Helen Huls; Simon Olivares; Dean A Lee; Richard E Champlin; Laurence J N Cooper
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

2.  Characterization of the immune cell repertoire in the normal fallopian tube.

Authors:  Laura Ardighieri; Silvia Lonardi; Daniele Moratto; Fabio Facchetti; Ie-Ming Shih; William Vermi; Robert J Kurman
Journal:  Int J Gynecol Pathol       Date:  2014-11       Impact factor: 2.762

3.  Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer.

Authors:  Jieti Wang; Chao Lin; He Li; Ruochen Li; Yifan Wu; Hao Liu; Heng Zhang; Hongyong He; Weijuan Zhang; Jiejie Xu
Journal:  Oncoimmunology       Date:  2017-07-24       Impact factor: 8.110

Review 4.  Therapeutic targeting of gastrointestinal cancer stem cells.

Authors:  Jonathan Stem; John C Flickinger; Dante Merlino; Ellen M Caparosa; Adam E Snook; Scott A Waldman
Journal:  Regen Med       Date:  2019-04-26       Impact factor: 3.806

5.  Immunobiology and signaling pathways of cancer stem cells: implication for cancer therapy.

Authors:  Mohamed L Salem; Ahmed S El-Badawy; Zihai Li
Journal:  Cytotechnology       Date:  2014-12-17       Impact factor: 2.058

Review 6.  Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

Authors:  Dingxiao Zhang; Dean G Tang; Kiera Rycaj
Journal:  Semin Cancer Biol       Date:  2018-05-09       Impact factor: 15.707

7.  Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer.

Authors:  T Xiang; H Long; L He; X Han; K Lin; Z Liang; W Zhuo; R Xie; B Zhu
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

Review 8.  Cancer stem cells as targets for immunotherapy.

Authors:  Amy S Codd; Takayuki Kanaseki; Toshihiko Torigo; Zsuzsanna Tabi
Journal:  Immunology       Date:  2017-12-18       Impact factor: 7.397

9.  Epithelial ovarian cancer stem-like cells expressing α-gal epitopes increase the immunogenicity of tumor associated antigens.

Authors:  Xiaofen Yao; Zhangli Dong; Qiuwan Zhang; Qian Wang; Dongmei Lai
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

Review 10.  Targeting gamma delta T cells for cancer immunotherapy: bench to bedside.

Authors:  Dimpu Gogoi; Shubhada V Chiplunkar
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.